keyword
MENU ▼
Read by QxMD icon Read
search

infection risk following biological therapy

keyword
https://www.readbyqxmd.com/read/29792084/lethal-disseminated-tuberculosis-in-patients-under-biological-treatment-two-clinical-cases-and-a-short-review
#1
Elena Dantes, Doina Ecaterina Tofolean, Ariadna Petronela Fildan, Liviu Craciun, Elena Dumea, Ioan Tiberiu Tofolean, Laura Mazilu
Tumour necrosis factor (TNF)-α inhibitors are highly used in Romania for the treatment of autoimmune disorders, such as rheumatoid arthritis (RA), psoriasis, inflammatory bowel diseases, and ankylosing spondylitis. Biological therapy using TNF-α inhibitors is very effective but is associated with an increased risk of opportunistic infections, including active tuberculosis. Here, two cases are presented of patients with RA and psoriasis under biological therapy who developed very aggressive forms of disseminated tuberculosis, with a rapid progression to death...
January 1, 2018: Journal of International Medical Research
https://www.readbyqxmd.com/read/29778738/risk-adapted-therapy-for-young-children-with-medulloblastoma-sjyc07-therapeutic-and-molecular-outcomes-from-a-multicentre-phase-2-trial
#2
Giles W Robinson, Vasilisa A Rudneva, Ivo Buchhalter, Catherine A Billups, Sebastian M Waszak, Kyle S Smith, Daniel C Bowers, Anne Bendel, Paul G Fisher, Sonia Partap, John R Crawford, Tim Hassall, Daniel J Indelicato, Frederick Boop, Paul Klimo, Noah D Sabin, Zoltan Patay, Thomas E Merchant, Clinton F Stewart, Brent A Orr, Jan O Korbel, David T W Jones, Tanvi Sharma, Peter Lichter, Marcel Kool, Andrey Korshunov, Stefan M Pfister, Richard J Gilbertson, Robert P Sanders, Arzu Onar-Thomas, David W Ellison, Amar Gajjar, Paul A Northcott
BACKGROUND: Young children with medulloblastoma have a poor overall survival compared with older children, due to use of radiation-sparing therapy in young children. Radiotherapy is omitted or reduced in these young patients to spare them from debilitating long-term side-effects. We aimed to estimate event-free survival and define the molecular characteristics associated with progression-free survival in young patients with medulloblastoma using a risk-stratified treatment strategy designed to defer, reduce, or delay radiation exposure...
May 16, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29757355/a-prospective-study-to-monitor-for-tuberculosis-during-anti-tumour-necrosis-factor-therapy-in-patients-with-inflammatory-bowel-disease-and-immune-mediated-inflammatory-diseases
#3
Choon Kin Lee, Sunny H Wong, Grace Lui, Whitney Tang, Lai San Tam, Margaret Ip, Esther Hung, Minhu Chen, Justin C Wu, Siew C Ng
Background: Biologic therapies have revolutionised the treatment of immune- mediated diseases including inflammatory bowel disease (IBD) and rheumatological disorders. However, biologic treatments are associated with an increased risk of reactivation of latent tuberculosis. Data of regular monitoring for latent tuberculosis infection (LTBI) during biologic treatment are lacking. Methods: Consecutive patients eligible for biologic therapies were screened for LTBI and prospectively followed-up for 3 years...
May 11, 2018: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/29756637/withdrawal-of-immunosuppressant-or-biologic-therapy-for-patients-with-quiescent-crohn-s-disease
#4
REVIEW
Ray K Boyapati, Joana Torres, Carolina Palmela, Claire E Parker, Orli M Silverberg, Sonam D Upadhyaya, Tran M Nguyen, Jean-Frédéric Colombel
BACKGROUND: Crohn's disease (CD) is a chronic, relapsing and remitting disease of the gastrointestinal tract that can cause significant morbidity and disability. Current treatment guidelines recommend early intervention with immunosuppressant or biological therapy in high-risk patients with a severe disease phenotype at presentation. The feasibility of therapeutic de-escalation once remission is achieved is a commonly encountered question in clinical practice, driven by patient and clinician concerns regarding safety, adverse events, cost and national regulations...
May 12, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29718223/outcomes-of-treatment-for-latent-tuberculosis-infection-in-patients-with-inflammatory-bowel-disease-receiving-biologic-therapy
#5
Guilherme P Ramos, Gregory Stroh, Badr Al-Bawardy, William A Faubion, Konstantinos A Papadakis, Patricio Escalante
Background: Treatment for latent tuberculosis infection (LTBI) is of particular concern in patients with inflammatory bowel disease (IBD) initiating biologic therapies to prevent tuberculosis (TB) reactivation. This study aimed to evaluate the effectiveness of LTBI treatment in IBD patients receiving biologic therapy. Methods: There was a retrospective review of all IBD patients diagnosed with LTBI following a tuberculin skin test (TST) and/or interferon gamma release assay (IGRA) and who received biologic therapy between 2002 and 2016...
April 26, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29589641/cutaneous-squamous-cell-carcinoma-complicating-hidradenitis-suppurativa-a-review-of-the-prevalence-pathogenesis-and-treatment-of-this-dreaded-complication
#6
Stephanie Chapman, Daniel Delgadillo III, Cara Barber, Amor Khachemoune
Hidradenitis suppurativa (HS) is a chronic and debilitating skin disorder characterized by the formation of painful abscesses, draining sinus tracts, and scarring, predominantly in skin folds such as the axillae and the perineum. The exact prevalence of HS is unknown because the disease is often underreported, but it has been estimated to be as high as 4.1%. HS is three times more prevalent in women than in men. Various comorbidities have been associated with HS, including inflammatory bowel disease and squamous cell carcinoma (SCC)...
March 2018: Acta Dermatovenerologica Alpina, Panonica, et Adriatica
https://www.readbyqxmd.com/read/29544969/cutibacterium-formerly-propionibacterium-avidum-a-rare-but-avid-agent-of-prosthetic-hip-infection
#7
Valérie A Zeller, Valérie-Anne Letembet, Vanina A Meyssonnier, Beate Heym, Jean-Marc Ziza, Simon D Marmor
BACKGROUND: Cutibacterium spp. (formerly Propionibacterium) are slow-growing cutaneous anaerobic commensals, rarely reported in prosthetic joint infections (PJIs). We describe epidemiological, clinical, biological, and radiological characteristics of 15 Cutibacterium avidum PJIs, their treatments, and outcomes. METHODS: This study is an observational, monocenter study (January 2004 to April 2017), with comparison of C avidum vs Cutibacterium acnes (n = 40) PJI characteristics...
February 12, 2018: Journal of Arthroplasty
https://www.readbyqxmd.com/read/29529307/opportunistic-infections-in-rheumatoid-arthritis-patients-exposed-to-biologic-therapy-results-from-the-british-society-for-rheumatology-biologics-register-for-rheumatoid-arthritis
#8
Andrew I Rutherford, Eunice Patarata, Sujith Subesinghe, Kimme L Hyrich, James B Galloway
Objectives: This analysis set out to estimate the risk of opportunistic infection (OI) among patients with RA by biologic class. Methods: The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis is a prospective observational cohort study established to evaluate safety of biologic therapies. The population included adults commencing biologic therapy for RA. The primary outcome was any serious OI excluding tuberculosis (TB). Event rates were compared across biologic classes using Cox proportional hazards with adjustment for potential confounders identified a priori...
February 26, 2018: Rheumatology
https://www.readbyqxmd.com/read/29504063/serious-non-aids-conditions-in-hiv-benefit-of-early-art
#9
REVIEW
Jens D Lundgren, Alvaro H Borges, James D Neaton
PURPOSE OF REVIEW: Optimal control of HIV can be achieved by early diagnosis followed by the initiation of antiretroviral therapy (ART). Two large randomised trials (TEMPRANO and START) have recently been published documenting the clinical benefits to HIV-positive adults of early ART initiation. Main findings are reviewed with a focus on serious non-AIDS (SNA) conditions. RECENT FINDINGS: Data from the two trials demonstrated that initiating ART early in the course of HIV infection resulted in marked reductions in the risk of opportunistic diseases and invasive bacterial infections...
April 2018: Current HIV/AIDS Reports
https://www.readbyqxmd.com/read/29459143/escmid-study-group-for-infections-in-compromised-hosts-esgich-consensus-document-on-the-safety-of-targeted-and-biological-therapies-an-infectious-diseases-perspective-soluble-immune-effector-molecules-i-anti-tumor-necrosis-factor-%C3%AE-agents
#10
REVIEW
J W Baddley, F Cantini, D Goletti, J J Gómez-Reino, E Mylonakis, R San-Juan, M Fernández-Ruiz, J Torre-Cisneros
BACKGROUND: The present review is part of the ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies. AIMS: To review, from an Infectious Diseases perspective, the safety profile of agents targeting tumour necrosis factor-α (TNF-α) and to suggest preventive recommendations. SOURCES: Computer-based MEDLINE searches with MeSH terms pertaining to each agent or therapeutic family...
February 6, 2018: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/29455561/rates-of-latent-tuberculosis-infection-in-patients-treated-with-tnf-inhibitors-for-psoriasis-a-retrospective-chart-review
#11
Erica B Lee, Mina Amin, Jeremy Man, Alexander Egeberg, Jashin J Wu
BACKGROUND: Although tuberculosis screening guidelines for psoriasis patients on TNF inhibitors exist, few studies have reported the prevalence of latent tuberculosis infection (LTBI) and conversion rates in this population. OBJECTIVE: To determine the incidence of LTBI and active tuberculosis in patients with psoriasis receiving TNF inhibitor therapy. METHODS: A total of 138 patients were included in our retrospective study of patients treated from September 2004 to September 2017...
March 22, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/29427801/escmid-study-group-for-infections-in-compromised-hosts-esgich-consensus-document-on-the-safety-of-targeted-and-biological-therapies-an-infectious-diseases-perspective-introduction
#12
REVIEW
M Fernández-Ruiz, Y Meije, O Manuel, H Akan, J Carratalà, J M Aguado, J Delaloye
BACKGROUND: The field of new biological agents is increasing exponentially over the past years, thus making prevention and management of associated infectious complications a challenge for nonspecialized clinicians. AIMS: The present consensus document is an initiative of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH) aimed at analysing, from an infectious diseases perspective, the safety of targeted and biological therapies...
February 7, 2018: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/29424301/novel-therapeutic-approaches-in-rheumatoid-arthritis-role-of-janus-kinases-inhibitors
#13
Felice Rivellese, Antonio Lobasso, Letizia Barbieri, Bianca Liccardo, Amato De Paulis, Francesca Wanda Rossi
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage and bone destruction and several systemic features. Cardiovascular, pulmonary, psychological, and muscle involvement are the main comorbidities of RA and are responsible for the severity of the disease and long-term prognosis. Pharmacological treatment of rheumatic diseases has evolved remarkably over the past years. In addition, the widespread adoption of treat to target and tight control strategies has led to a substantial improvement of outcomes, so that drug-free remission is nowadays a realistic goal in the treatment of RA...
February 9, 2018: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/29363355/biologic-induced-infections-in-inflammatory-bowel-disease-the-tnf-%C3%AE-antagonists
#14
Sean M McConachie, Sheila M Wilhelm, Ashish Bhargava, Pramodini B Kale-Pradhan
OBJECTIVE: To review the mechanism and association of infectious risk among the tumor-necrosis factor α (TNF-α) antagonists used in inflammatory bowel disease. DATA SOURCES: A PubMed literature search was performed using the following search terms: infliximab, adalimumab, certolizumab, golimumab, inflammatory bowel disease, crohn's, ulcerative colitis, adverse effects, adverse events, safety, and infection. STUDY SELECTION AND DATA EXTRACTION: Meta-analyses and cohort studies with outcomes pertaining to quantitative infectious risk were reviewed...
January 1, 2018: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/29345515/safety-of-biologic-agents-for-psoriasis-in-patients-with-viral-hepatitis
#15
Nawaf AlMutairi, Hesham Alaadin Abouzaid
INTRODUCTION: Biologics are highly effective, important treatment options for moderate-to-severe psoriasis. Biologics are well tolerated and have few side effects. However, the use of biologics in patients with concomitant chronic viral hepatitis is debatable. Recent reports have suggested a very low associated risk of reactivation of chronic hepatitis B (HBV) and C (HCB). OBJECTIVE: To evaluate the safety and effectiveness of biologics for moderate to severe psoriasis patients with concomitant chronic viral hepatitis...
January 18, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/29343274/coexistent-sickle-cell-anemia-and-autoimmune-disease-in-eight-children-pitfalls-and-challenges
#16
Valerie Li-Thiao-Te, Florence Uettwiller, Pierre Quartier, Florence Lacaille, Brigitte Bader-Meunier, Valentine Brousse, Mariane de Montalembert
BACKGROUND: Patients with sickle cell disease (SCD) present a defective activation of the alternate complement pathway that increases the risk of infection and is thought to predispose to autoimmune disease (AID). However, coexisting AID and SCD is rarely reported, suggesting possible underdiagnosis due to an overlapping of the symptoms. STUDY DESIGN: Among 603 patients with SCD followed between 1999 and June 2016, we retrospectively searched for patients with coexisting SCD and AID...
January 17, 2018: Pediatric Rheumatology Online Journal
https://www.readbyqxmd.com/read/29216396/short-term-efficacy-and-safety-of-rituximab-therapy-in-refractory-systemic-lupus-erythematosus-results-from-the-british-isles-lupus-assessment-group-biologics-register
#17
Eoghan M McCarthy, Emily Sutton, Stephanie Nesbit, James White, Ben Parker, David Jayne, Bridget Griffiths, David A Isenberg, Anisur Rahman, Caroline Gordon, David P D'Cruz, Benjamin Rhodes, Peter Lanyon, Edward M Vital, Chee-Seng Yee, Christopher J Edwards, Lee-Suan Teh, Mohammed Akil, Neil J McHugh, Asad Zoma, Ian N Bruce
Objectives: To describe the baseline characteristics of SLE patients requiring biologic therapy in the UK and to explore short term efficacy and infection rates associated with rituximab (RTX) use. Methods: Patients commencing biologic therapy for refractory SLE and who consented to join BILAG-BR were analysed. Baseline characteristics, disease activity (BILAG 2004/SLEDAI-2K) and rates of infection over follow-up were analysed. Response was defined as loss of all A and B BILAG scores to ⩽ 1 B score with no new A/B scores in other organ systems at 6 months...
March 1, 2018: Rheumatology
https://www.readbyqxmd.com/read/29081304/genotype-and-genetic-variation-of-hcv-infections-with-low-risk-factors-in-putian-coastal-regions-china
#18
X M Li, R X Qiu, C H Song, Q H Huang, X D Wang, Z T Hu, X Z He, X Y Ye, X G Huang, F F Zheng, G X Lin
Hepatitis C virus (HCV) infection is one of the leading causes of death and morbidity associated with liver disease. Risk factors identified for the transmission of HCV include contaminated blood products, intravenous drug use, body piercing, an infected mother at birth, sexual activity, and dental therapy, among others. However, the exact diversity of the HCV genotype and genetic variation among patients with low-risk factors is still unknown. In this study, we briefly described and analysed the genotype distribution and genetic variation of HCV infections with low-risk factors using molecular biology techniques...
December 2017: Epidemiology and Infection
https://www.readbyqxmd.com/read/29021093/disseminated-cryptococcosis-in-a-patient-taking-tocilizumab-for-castleman-s-disease
#19
Hiroaki Nishioka, Hiroshi Takegawa, Hiroki Kamei
Infections occur more frequently in patients receiving biologics. However, cryptococcal infection is uncommon in patients receiving tocilizumab, an interleukin-6 inhibitor, in contrast to patients receiving tumor necrosis factor-α inhibitors. In this report, we describe a case of disseminated cryptococcosis in a 55-year-old man who was receiving tocilizumab every 2 weeks along with daily prednisolone and cyclosporine for Castleman's disease. He initially developed cellulitis on both upper limbs, and his condition worsened despite antibacterial therapy...
February 2018: Journal of Infection and Chemotherapy: Official Journal of the Japan Society of Chemotherapy
https://www.readbyqxmd.com/read/28978417/detection-and-treatment-of-fiebig-stage-i-hiv-1-infection-in-young-at-risk-women-in-south-africa-a-prospective-cohort-study
#20
Krista L Dong, Amber Moodley, Douglas S Kwon, Musie S Ghebremichael, Mary Dong, Nasreen Ismail, Zaza M Ndhlovu, Jenniffer M Mabuka, Daniel M Muema, Karyn Pretorius, Nina Lin, Bruce D Walker, Thumbi Ndung'u
BACKGROUND: HIV incidence among young women in sub-Saharan Africa remains high and their inclusion in vaccine and cure efforts is crucial. We aimed to establish a cohort of young women detected during Fiebig stage I acute HIV infection in whom treatment was initiated immediately after diagnosis to advance research in this high-risk group. METHODS: 945 women aged 18-23 years in KwaZulu-Natal, South Africa, who were HIV uninfected and sexually active consented to HIV-1 RNA testing twice a week and biological sampling and risk assessment every 3 months during participation in a 48-96 week life-skills and job-readiness programme...
January 2018: Lancet HIV
keyword
keyword
104481
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"